Author

Kunzhong Wu

Nankai University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:graph neural network· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

Hongming CheniD· 2 shared Jinsai ShangiD· 2 shared Miru Tang· 2 shared Ting RaniD· 2 shared Xinwen CheniD· 2 shared Yongzhi LuiD· 2 shared Anqi ZhouiD· 1 shared Bao Xue· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

Hongming ChenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A novel AR molecular glue degrader via bivalent engagement of the N-terminal domain and RNF213-UBE2J2 complex

Kunzhong Wu, Qiong Wu, Yongzhi Lu, Qi Yang, Ting Ran, Jie Zhang, Xianjie Qiu, Chengjie Huang, Yue Lin, J K Chen, Z L Yang, Wei Qin, Zhu Liu, Xinqi Liu, Miru Tang, , Jinsai Shang

This paper introduces GZL626, a novel AR degrader that targets the N-terminal domain and RNF213-UBE2J2 complex, effectively degrading AR and AR-V7 and showing antitumor and antiviral activity.

bioRxiv · Jul 16, 2026 · PreprintBiophysics

Discovery of resistance-resilient quinoline papain-like protease inhibitors through topology-constrained molecular generative design

Yongzhi Lu, Ting Ran, Qi Yang, Guihua Zhang, Jiayi Chen, Peiqi Zhou, Wenqi Li, Minyuan Xu, Jielin Tang, Minxian Dai, Jinpeng Zhong, Hua Chen, Pan He, Anqi Zhou, Bao Xue, , Jinsai Shang

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.

bioRxiv · Sep 7, 2024 · PreprintMicrobiology